Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nichi-Iko Asks for Debt Waiver from Creditors in Turnaround Plan
Nichi-Iko Pharmaceutical on November 16 presented its draft business restructuring plan to creditors as part of an out-of-court turnaround procedure initiated earlier this year, seeking debt forgiveness from all financial institutions. The draft plan was submitted at the second creditor…
To read the full story
Related Article
- Shingo Iwamoto Sworn in as New Chief of Nichi-Iko; Tamura Bows Out
March 9, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
- Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
- Shareholders OK Nichi-Iko’s Delisting, Turnaround under New Management; President to Exit March 8
February 20, 2023
- Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
- Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
January 5, 2023
- Mediator Sees Potential for Turnaround in Nichi-Iko’s Restructuring Plan
November 28, 2022
- Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
November 15, 2022
- Nichi-Iko Logs 35.6 Billion Yen in Excess Debt in April-September
November 15, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Creditors Defer Debts for Nichi-Iko until Turnaround Plan Is Approved
May 27, 2022
- Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
- Nichi-Iko Files for Debt Reorganization, Incurs Loss of Over 100 Billion Yen
May 13, 2022
BUSINESS
- Sandoz Poaches Regeneron’s Yohei Ishii as Japan Chief
April 30, 2026
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
April 30, 2026
- Otsuka’s IgA Drug Voyxact Sees Strong US Uptake: EVP
April 30, 2026
- KM Biologics, India’s Serum Institute Partner on Japanese Encephalitis Vaccine
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…